New diabetes therapy using FGF1 analogues. (Q84115): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Fixing rounding issue)
(‎Removed claim: summary (P836): Diabetes is currently among the most serious problems of civilisation in the world.The number of people with diabetes is constantly increasing and associated complications are a danger to patients’ health and life.In spite of advances in medicine, treatments continue to have a number of undesirable side-effects, such as the risk of under-glucose in the blood (hypoglycaemia), fatty infiltration of the liver or a decrease in bone weight.The aim...)
Property / summary
Diabetes is currently among the most serious problems of civilisation in the world.The number of people with diabetes is constantly increasing and associated complications are a danger to patients’ health and life.In spite of advances in medicine, treatments continue to have a number of undesirable side-effects, such as the risk of under-glucose in the blood (hypoglycaemia), fatty infiltration of the liver or a decrease in bone weight.The aim of the project is to develop an innovative and original diabetes medicine, based on FGF1 analogue protein (the growth factor of the minor;The Fibgrave Growth Factor), which will give patients with type II diabetes a new alternative therapy for unobtrusive effects.The project involves the R & D work on a global biotechnology medicine technology.The project will result in the development and market implementation of the original diabetes therapy FGF1 as applied for diabetes therapy.The implementation of the results of the project will lead to a breakthrough in the treatment of diabetes and will address both the problem of the regeneration of beta cells and insulin resistance.The project will run for a period of 70 months in 4 steps.The first 3 stages will consist of conducting industrial research on the development of the structures of innovative proteins, their testing in in vitro and in vivo systems and their production and characterisation.The results of these tests will result in the selection of a candidate for preclinical development and the development of an industrial production process.The last part, closing the project, will be the development work consisting of the preparation of the supporting documentation of the CTA and the conduct of a clinical trial and phase I.The project’s objectives will be supported by a rich knowledge and experience of the applicant and an effective support (English)
 
Property / summary: Diabetes is currently among the most serious problems of civilisation in the world.The number of people with diabetes is constantly increasing and associated complications are a danger to patients’ health and life.In spite of advances in medicine, treatments continue to have a number of undesirable side-effects, such as the risk of under-glucose in the blood (hypoglycaemia), fatty infiltration of the liver or a decrease in bone weight.The aim of the project is to develop an innovative and original diabetes medicine, based on FGF1 analogue protein (the growth factor of the minor;The Fibgrave Growth Factor), which will give patients with type II diabetes a new alternative therapy for unobtrusive effects.The project involves the R & D work on a global biotechnology medicine technology.The project will result in the development and market implementation of the original diabetes therapy FGF1 as applied for diabetes therapy.The implementation of the results of the project will lead to a breakthrough in the treatment of diabetes and will address both the problem of the regeneration of beta cells and insulin resistance.The project will run for a period of 70 months in 4 steps.The first 3 stages will consist of conducting industrial research on the development of the structures of innovative proteins, their testing in in vitro and in vivo systems and their production and characterisation.The results of these tests will result in the selection of a candidate for preclinical development and the development of an industrial production process.The last part, closing the project, will be the development work consisting of the preparation of the supporting documentation of the CTA and the conduct of a clinical trial and phase I.The project’s objectives will be supported by a rich knowledge and experience of the applicant and an effective support (English) / rank
Normal rank
 

Revision as of 14:30, 14 October 2020

Project in Poland financed by DG Regio
Language Label Description Also known as
English
New diabetes therapy using FGF1 analogues.
Project in Poland financed by DG Regio

    Statements

    country
    Poland
    0 references
    EU contribution
    9,941,542.38 zloty
    0 references
    2,385,970.17 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    budget
    13,396,154.28 zloty
    0 references
    3,215,077.03 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    co-financing rate
    74.21 percent
    0 references
    start time
    1 March 2016
    0 references
    end time
    31 December 2021
    0 references
    beneficiary name (string)
    CELON PHARMA S.A.
    0 references
    beneficiary
    Q2509662
    0 references
    summary
    Cukrzyca zaliczana jest obecnie do najpoważniejszych schorzeń cywilizacyjnych na świecie. Liczba chorych na cukrzycę wciąż wzrasta, a towarzyszące jej powikłania stanowią niebezpieczeństwo dla zdrowia i życia pacjentów. Mimo postępów w medycynie, stosowane terapie nadal posiadają szereg niepożądanych efektów ubocznych, takich jak ryzyko wystąpienia zbyt niskiego poziomu glukozy we krwi (hipoglikemia), stłuszczenie wątroby czy spadek masy kości. Celem projektu jest opracowanie innowacyjnego i oryginalnego leku przeciwcukrzycowego, opartego na analogu białka FGF1 (czynnik wzrostu fibroblastów, ang. Fibroblast Growth Factor), który dzięki swoim właściwościom przeciwcukrzycowym będzie stanowił dla pacjentów cierpiących na cukrzycę typu II nową, alternatywną terapię nieobarczoną skutkami ubocznymi. Projekt obejmuje prace B+R nad innowacyjnym w skali światowej lekiem biotechnologicznym. Efektem projektu będzie opracowanie oraz wdrożenie na rynek oryginalnego analogu białka FGF1 stosowanego w terapii cukrzycy. Wdrożenie rezultatów projektu doprowadzi do przełomu w leczeniu cukrzycy i pozwoli na rozwiązanie zarówno problemu regeneracji komórek beta oraz insulinooporności. Projekt realizowany będzie przez okres 70 miesięcy w 4 etapach. Pierwsze 3 etapy będą polegać na prowadzeniu badań przemysłowych nad opracowaniem struktur innowacyjnych białek, ich testowaniu w układach in vitro i in vivo oraz ich produkcji i charakteryzacji. Efektem tych badań będzie wybór kandydata do rozwoju przedklinicznego i opracowanie procesu produkcji przemysłowej. Ostatnią częścią, zamykającą projekt będą prace rozwojowe, polegające na przygotowaniu dokumentacji CTA oraz przeprowadzenie badania klinicznego I fazy. W osiągnięciu celów projektu wykorzystane zostaną bogata wiedza i doświadczenie wnioskodawcy oraz skuteczna wsp (Polish)
    0 references

    Identifiers

    Polish Kohesio ID
    POIR.04.01.04-00-0117/15
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q84115&oldid=6347600"